WHO Technical Report Series

1019

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Fifty-third report

World Health Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing diseases prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaption. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. To purchase WHO publications, please contact: WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int; http://www.who.int/bookorders).

WHO Technical Report Series
1019

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Fifty-third report

This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization

World Health Organization

WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-third report

(WHO Technical Report Series, No. 1019)

ISBN 978-92-4-121028-7
ISSN 0512-3054

Suggested citation. WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-third report. Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1019). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Printed in Italy

Contents

Abbreviations vii

WHO Expert Committee on Specifications for Pharmaceutical Preparations ix

Introduction 1

1. General policy 4

1.1 Process for the development of WHO norms and standards 4
1.2 Participation in meetings of the Expert Committee on Specifications for Pharmaceutical Preparations 5
1.3 Open session 6
1.3.1 Introduction and welcome 6

2. General updates and matters for information 8

2.1 Cross-cutting pharmaceutical quality assurance issues 8
2.1.1 Local manufacturing 8
2.1.2 Member State mechanism 9
2.1.3 Expert Committee on Biological Standardization 9
2.1.4 Expert Committee – selection and use of the *WHO Model List of Essential Medicines* 10
2.1.5 Antimicrobial resistance 11
2.1.6 International Conference of Drug Regulatory Authorities 12
2.2 International collaboration 12
2.2.1 International Atomic Energy Agency 12
2.2.2 Pharmacopoeial Discussion Group 13
2.2.3 United Nations Children's Fund 13

3. Quality assurance – collaboration initiatives 15

3.1 International meetings of world pharmacopoeias 15
3.2 Inspection guidelines and good practices 15
3.2.1 Revision of *WHO good manufacturing practices for sterile pharmaceutical products* 15
3.2.2 *Good manufacturing practices for biotherapeutic products* 16

4. Nomenclature, terminology and databases 18

4.1 International Nonproprietary Names for pharmaceutical substances 18
4.2 Quality assurance terminology 18
4.3 Guidelines and guidance texts adopted by the Expert Committee 18

5. Prequalification of priority essential medicines and active pharmaceutical ingredients 20

5.1 Update on the prequalification of medicines 20
5.2 Update on the prequalification of active pharmaceutical ingredients 20

6. Quality control – prequalification and WHO monitoring projects 22

6.1 Update on the prequalification of quality control laboratories 22
6.2 Update on WHO quality monitoring projects 22

7. Quality control – national laboratories 23
7.1 External Quality Assurance Assessment Scheme 23

8. Quality control – specifications and tests: *The International Pharmacopoeia* 24
8.1 Update 24
8.2 Workplan 2018–2019 24
8.3 Procedure for the development, revision and omission of monographs and other texts for *The International Pharmacopoeia* 26
8.4 General policy – transition from microbiological to physicochemical assays in monographs on capreomycin active pharmaceutical ingredient and products 27
8.5 General chapters 27
8.5.1 Limit test for heavy metals 27
8.5.2 Polymorphism 28
8.5.3 Dissolution test for solid oral dosage forms 29
8.5.4 General notice: solubility 29
8.6 Specifications and draft monographs for medicines, including paediatric and radiopharmaceutical medicines 29
8.6.1 Medicines for maternal, newborn, child and adolescent health 29
8.6.2 Antimalarial medicines 31
8.6.3 Antituberculosis medicines 31
8.6.4 Antiviral medicines including antiretrovirals 32
8.6.5 Medicines for tropical diseases 33
8.6.6 Ophthalmological and dermatological medicines 34

9. Quality control – international reference materials 35
9.1 Update on International Chemical Reference Substances, including the report of the custodial centre of the dedicated ECSPP subgroup on the International Chemical Reference Substances 35

10. General policy – chemistry 36
10.1 Revision of guidance on representation of graphic formulae 36

11. Quality assurance – good manufacturing practices and inspection 37
11.1 Interpretation of *Guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems* 37
11.2 Good manufacturing practices for validation 38
11.2.1 General main text 38
11.2.2 Analytical procedure validation 39
11.2.3 Validation of computerized systems 40
11.2.4 Qualification 40
11.3 Update on review of existing WHO inspection guidance, including *Guidelines for inspection of drug distribution channels and Quality system requirements for national good manufacturing practice inspectorates* 41
11.3.1 Guidelines for inspection of drug distribution channels 42
11.3.2 Quality system requirements for national good manufacturing practice inspectorates 42
11.4 Update and recommendations from inspectors' meeting, including on good manufacturing practices and environmental issues 42

11.5 Inquiry regarding production of "water for injection" 43
11.6 Proposal for good chromatography practices 44

12. Quality assurance – distribution and supply chain 45

12.1 Guidelines on import procedures for medical products 45
12.2 Update on review of existing WHO guidance, procedures and operational documents for pharmaceutical procurement 45
12.2.1 New guidance on shelf-life for supply and procurement of medicines 45
12.2.2 Update of listing of stability conditions for WHO Member States 46

13. Regulatory guidance and model schemes 47

13.1 Proposal to waive in vivo bioequivalence requirements for medicines included in the *WHO Model List of Essential Medicines* 47
13.1.1 Experimental pathway 48
13.1.2 Regulatory pathway 49
13.1.3 Prioritization exercise 49
13.2 WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce 50
13.3 Good practice guidance document on implementing the collaborative procedures 51
13.4 Guidance document to support and facilitate the implementation of quality management systems for national regulatory authorities 52
13.5 Good regulatory practices 52

14. Miscellaneous 53

14.1 Update of WHO/UNFPA prequalification guidance for contraceptive devices and condoms 53

15. Closing remarks 54

16. Summary and recommendations 55

Acknowledgements 60

References 83

Annex 1

Procedure for the development of World Health Organization medicines quality assurance guidelines 87

Annex 2

Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products
Part 2: Interpretation of *Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products* 93

Annex 3

Good manufacturing practices: guidelines on validation 119
Appendix 1 Validation of heating, ventilation and air-conditioning systems 135
Appendix 2 Validation of water systems for pharmaceutical use 136
Appendix 3 Cleaning validation 137
Appendix 4 Analytical procedure validation 148

Appendix 5 Validation of computerized systems 160
Appendix 6 Guidelines on qualification 181
Appendix 7 Non sterile process validation 190

Annex 4

Protocol to conduct equilibrium solubility experiments for the purpose of Biopharmaceutics Classification System-based classification of active pharmaceutical ingredients for biowaiver 203

Annex 5

Guidelines on import procedures for medical products 219

Annex 6

Good practices of national regulatory authorities in implementing the collaborative registration procedures for medical products 233
Appendix 1 An example of information to applicants for registration via the WHO collaborative registration procedure 257
Appendix 2 Verification for product submitted under the WHO collaborative procedure 259
Appendix 3 Abridged/abbreviated review for product submitted under the WHO collaborative procedure 263
Appendix 4 Additional information to be included in the screening checklist 279
Appendix 5 Example of a national regulatory authority reliance model approach: information, documentary evidence and assessment activity 281
Appendix 6 Model acknowledgement or approval letter for variations of products registered through the WHO collaborative procedure 283